These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34633420)

  • 1. Paying for Cancer Drugs That Prove Their Benefit.
    Frank RG; Emanuel EJ
    JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
    [No Abstract]   [Full Text] [Related]  

  • 2. Medicare challenges and solutions--reimbursement issues in treating the patient with colorectal cancer.
    Kaa K
    J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S19-26. PubMed ID: 17713991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model.
    Hwang TJ; LaMattina JL
    JAMA Oncol; 2016 Sep; 2(9):1125-6. PubMed ID: 27388928
    [No Abstract]   [Full Text] [Related]  

  • 4. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 5. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 6. Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
    Gordan L; Grogg A; Blazer M; Fortner B
    J Oncol Pract; 2017 Feb; 13(2):e139-e151. PubMed ID: 28029298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal cancer: complexities and challenges in managed care.
    Minkoff NB
    J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S27-9. PubMed ID: 17713992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The drug that could have been.
    Schultz S
    US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
    [No Abstract]   [Full Text] [Related]  

  • 9. Reimbursing Wisely? CMS's Trial of Medicare Part B Drug Payment Reform.
    Schrag D
    N Engl J Med; 2016 Jun; 374(22):2101-5. PubMed ID: 27248616
    [No Abstract]   [Full Text] [Related]  

  • 10. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.
    Hsiue EH; Moore TJ; Alexander GC
    Clin Trials; 2020 Apr; 17(2):119-125. PubMed ID: 32114790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare drug expansion causes controversy in the USA.
    Bristol N
    Lancet; 2009 Feb; 373(9663):532. PubMed ID: 19230076
    [No Abstract]   [Full Text] [Related]  

  • 12. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
    Gordon N; Stemmer SM; Greenberg D; Goldstein DA
    J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.
    Bach PB; Giralt SA; Saltz LB
    JAMA; 2017 Nov; 318(19):1861-1862. PubMed ID: 28975266
    [No Abstract]   [Full Text] [Related]  

  • 15. Expensive cancer therapies: unintended effects.
    Delude CM
    J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
    [No Abstract]   [Full Text] [Related]  

  • 16. Using cancer registries to supplement clinical trial data and inform regulatory decision.
    da Costa FA; da Costa Miranda A
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1319-1321. PubMed ID: 31788909
    [No Abstract]   [Full Text] [Related]  

  • 17. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
    Mailankody S; Prasad V
    JAMA; 2016 Jul; 316(3):271-2. PubMed ID: 27149663
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing Medicare's Approach To Covering New Drugs In Bundled Payments For Oncology.
    Muldoon LD; Pelizzari PM; Lang KA; Vandigo J; Pyenson BS
    Health Aff (Millwood); 2018 May; 37(5):743-750. PubMed ID: 29733731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upcoming market catalysts in Q4 2020.
    Pablos L
    Nat Rev Drug Discov; 2020 Oct; 19(10):661. PubMed ID: 32901130
    [No Abstract]   [Full Text] [Related]  

  • 20. Oncology drugs enter the US market faster than in Europe but cost more.
    Mitka M
    JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.